Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

A variety of chemotherapeutic agents have been used for treating recurrent or advanced stage uterine leiomyosarcoma (ULMS). The response rates of these current agents are disappointing, with partial response rates varying from 0% to 33%, and complete response rates varying from 0% to 8%. Recent stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Momtahen, Shabnam, Curtin, John, Mittal, Khush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737027/
https://www.ncbi.nlm.nih.gov/pubmed/26858789
http://dx.doi.org/10.14740/jocmr2419w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737027/
https://www.ncbi.nlm.nih.gov/pubmed/26858789
http://dx.doi.org/10.14740/jocmr2419w

Ejemplares similares